Product Description
AGPAT2 Antibody | 31-341 | ProSci
Host: Rabbit
Reactivity: Human
Homology: N/A
Immunogen: Antibody produced in rabbits immunized with a synthetic peptide corresponding a region of human AGPAT2.
Research Area: Membrane, Cancer
Tested Application: E, WB
Application: AGPAT2 antibody can be used for detection of AGPAT2 by ELISA at 1:312500. AGPAT2 antibody can be used for detection of AGPAT2 by western blot at 5.0 μg/mL, and HRP conjugated secondary antibody should be diluted 1:50, 000 - 100, 000.
Specificiy: N/A
Positive Control 1: Cat. No. 1205 - Jurkat Cell Lysate
Positive Control 2: N/A
Positive Control 3: N/A
Positive Control 4: N/A
Positive Control 5: N/A
Positive Control 6: N/A
Molecular Weight: 27 kDa, 31 kDa
Validation: N/A
Isoform: N/A
Purification: Antibody is purified by protein A chromatography method.
Clonality: Polyclonal
Clone: N/A
Isotype: N/A
Conjugate: Unconjugated
Physical State: Liquid
Buffer: Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose.
Concentration: batch dependent
Storage Condition: For short periods of storage (days) store at 4˚C. For longer periods of storage, store AGPAT2 antibody at -20˚C. As with any antibody avoid repeat freeze-thaw cycles.
Alternate Name: AGPAT2, 1-AGPAT2, BSCL, BSCL1, LPAAB, LPAAT-beta
User Note: Optimal dilutions for each application to be determined by the researcher.
BACKGROUND: AGPAT2 is a member of the 1-acylglycerol-3-phosphate O-acyltransferase family. The protein is located within the endoplasmic reticulum membrane and converts lysophosphatidic acid to phosphatidic acid, the second step in de novo phospholipid biosynthesis. Mutations in its gene have been associated with congenital generalized lipodystrophy (CGL) , or Berardinelli-Seip syndrome, a disease characterized by a near absence of adipose tissue and severe insulin resistance.This gene encodes a member of the 1-acylglycerol-3-phosphate O-acyltransferase family. The protein is located within the endoplasmic reticulum membrane and converts lysophosphatidic acid to phosphatidic acid, the second step in de novo phospholipid biosynthesis. Mutations in this gene have been associated with congenital generalized lipodystrophy (CGL) , or Berardinelli-Seip syndrome, a disease characterized by a near absence of adipose tissue and severe insulin resistance. Alternate transcriptional splice variants, encoding different isoforms, have been characterized.